ASCO 2023 Mark Reisenauer

ASCO 2023 – Mark Reisenauer

As we approach the last of our exclusive coverage of ASCO 2023, editor-in-chief Jonah Comstock speaks with Mark Reisenauer, president of US commercial at Astellas.

ASCO 2023 Warner Biddle

ASCO 2023 – Warner Biddle

While ASCO 2023 didn’t have too much focus on cell therapies, because of their lack of impact so far on the solid tumour space, Kite, a Gilead company, did share new data on Yescarta for la

ASCO 2023 Jennifer Elliott

ASCO 2023 – Jennifer Elliott

Some of the most impactful news out of ASCO 2023 dealt with new treatments for patients with few options in the status quo of cancer care.

ASCO 2023 Janssen

ASCO 2023 – Martin Vogel and Edmond Chan

In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.

ASCO 2023 Corina Dutcus

ASCO 2023 – Corina Dutcus

At ASCO 2023 last week in Chicago, editor-in-chief Jonah Comstock caught up with Dr Corina Dutcus, SVP clinical development at Eisai US, to talk about the CLEAR trial, one of Eisai’s major

ASCO 2023

ASCO 2023 – Gregory Lubiniecki

With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.